Loading presentation...

Present Remotely

Send the link below via email or IM

Copy

Present to your audience

Start remote presentation

  • Invited audience members will follow you as you navigate and present
  • People invited to a presentation do not need a Prezi account
  • This link expires 10 minutes after you close the presentation
  • A maximum of 30 users can follow your presentation
  • Learn more about this feature in our knowledge base article

Do you really want to delete this prezi?

Neither you, nor the coeditors you shared it with will be able to recover it again.

DeleteCancel

Make your likes visible on Facebook?

Connect your Facebook account to Prezi and let your likes appear on your timeline.
You can change this under Settings & Account at any time.

No, thanks

guillian barre syndrome

case presentation and topic review
by

khaled alamri

on 10 May 2013

Comments (0)

Please log in to add your comment.

Report abuse

Transcript of guillian barre syndrome

Prepared by: Case Presentation & Topic Review Medications Lab Results Vital Signs Supervised by: khaled Al-Amri pharm.D candidate
King Saud University Dr.Shatha Al-Samarrai
GICU consultant clinical pharmacist -PSMMC 11/November/2012

Definition

Epidemiology

Pathophysiology

Clinical presentation

Lab finding

Prognosis

Treatment

Summary Case presentation Topic review: Past Medical History: Social and Family History: Diabetes mellitus type 2
Hypertention,
Asthma Non
Emergency room Vital Signs Laboratory Results on admission Medications Previous Medications Current Medications
in ICU problem List: Guillain Barre Syndrome
Infection Allergies: No known allergies Outline ,pharm.D Big and.... ... small problem#1 Infection problem#2 Guillain Barre Syndrome
GBS Jacobs BC, Koga M, van Rijs W, Geleijns K, van Doorn PA, Willison HJ, et al. Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome. J Neuroimmunol. Feb 2008;180-190 Anita McGrogan a Gemma C. Madle b Hel.en E. Seaman b Corinne S. de Vries ,The Epidemiology of Guillain-Barré Syndrome Worldwide,Neuroepidemiology 2009;32:150–163 Anita McGrogan a Gemma C. Madle b Hel.en E. Seaman b Corinne S. de Vries ,The Epidemiology of Guillain-Barré Syndrome Worldwide,Neuroepidemiology 2009;32:150–163 Geleijns K, Roos A, Houwing-Duistermaat JJ, van Rijs W, Tio-Gillen AP, Laman JDet al. Mannose-binding lectin contributes to the severity of Guillain-Barré syndrome. J Immunol. Sep 15 2006;177(6):4211-7 Geleijns K, Roos A, Houwing-Duistermaat JJ, van Rijs W, Tio-Gillen AP, Laman JDet al. Mannose-binding lectin contributes to the severity of Guillain-Barré syndrome. J Immunol. Sep 15 2006;177(6):4211-7 Geleijns K, Roos A, Houwing-Duistermaat JJ, van Rijs W, Tio-Gillen AP, Laman JDet al. Mannose-binding lectin contributes to the severity of Guillain-Barré syndrome. J Immunol. Sep 15 2006;177(6):4211-7 Geleijns K, Roos A, Houwing-Duistermaat JJ, van Rijs W, Tio-Gillen AP, Laman JDet al. Mannose-binding lectin contributes to the severity of Guillain-Barré syndrome. J Immunol. Sep 15 2006;177(6):4211-7 Ruts, Bart C Jacobs,Clinical features, pathogenesis,and treatment ofGuillain-Barré syndrome,Lancet Neurol 2008; 7: 939–50 Ruts, Bart C Jacobs,Clinical features, pathogenesis,and treatment ofGuillain-Barré syndrome,Lancet Neurol 2008; 7: 939–50 Ruts, Bart C Jacobs,Clinical features, pathogenesis,and treatment ofGuillain-Barré syndrome,Lancet Neurol2008; 7: 939–50 Ruts, Bart C Jacobs,Clinical features, pathogenesis,and treatment ofGuillain-Barré syndrome,Lancet Neurol 2008; 7: 939–50 Ruts, Bart C Jacobs,Clinical features, pathogenesis,and treatment ofGuillain-Barré syndrome,Lancet Neurol 2008; 7: 939–50 Ruts, Bart C Jacobs,Clinical features, pathogenesis,and treatment ofGuillain-Barré syndrome,Lancet Neurol 2008; 7: 939–5 Ruts, Bart C Jacobs,Clinical features, pathogenesis,and treatment ofGuillain-Barré syndrome,Lancet Neurol 2008; 7: 939–50 History of Present Illness Cont;history of Present Illness Case Presentation Ruts, Bart C Jacobs,Clinical features, pathogenesis,and treatment ofGuillain-Barré syndrome,Lancet Neurol 2008; 7: 939–50 Ruts, Bart C Jacobs,Clinical features, pathogenesis,and treatment ofGuillain-Barré syndrome,Lancet Neurol 2008; 7: 939–50 3 1- 2- Jacobs BC, Koga M, van Rijs W, Geleijns K, van Doorn PA, Willison HJ, et al. Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome. J Neuroimmunol. Feb 2008;180-190 Jacobs BC, Koga M, van Rijs W, Geleijns K, van Doorn PA, Willison HJ, et al. Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome. J Neuroimmunol. Feb 2008;180-190 Jacobs BC, Koga M, van Rijs W, Geleijns K, van Doorn PA, Willison HJ, et al. Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome. J Neuroimmunol. Feb 2008;180-190 11
Full transcript